044 – Marker Therapeutics DISAPPOINTS in pancreatic cancer

Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic cancer. I go through the data in all 3 arms and analyze whether or not they see an actual effect of their unique therapy.

*this is not investment advice*

#breaking biotech #biotech

 

Leave a Reply

%d bloggers like this: